Patent number: 7705042
Abstract: The invention relates to arylamide and hetereoarylamide compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
Type:
Grant
Filed:
October 20, 2005
Date of Patent:
April 27, 2010
Assignee:
Janssen Pharmaceutica NV
Inventors:
Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath Meegalla, Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee DesJarlais, Carl L. Manthey, Christopher M. Flores, Christopher J. Molloy